CD33 and breast cancer: In our previous study, we identified a subset of poorly differentiated eMDSCs in breast cancer that expressed an immature phenotype of Lin−HLA-DR−CD45+CD33+CD13+CD14−CD15− and displayed potent suppression of T cells in vitro and in vivo (6).